Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Foresees Broad Insurance Coverage For Groundbreaking Spravato Nasal Spray

Executive Summary

Datamonitor projects the newly US FDA-approved esketamine product for treatment-resistant depression will reach sales of almost $2bn in the US, Japan and five major European markets.

You may also be interested in...



US FDA Opens Door For J&J's Spravato To Another MDD Population

The US FDA approved the esketamine nasal spray for adults with major depressive disorder with suicidal ideation or behavior, following its initial approval in 2019 for treatment-resistant depression. 

J&J Looks To Expand Spravato Label To Suicidal Ideation

The big pharma will seek the new indication later this year based on Phase III data showing a rapid decrease in depression symptoms, but without a significant improvement over placebo in suicidality.

J&J Leverages Novel Mechanisms In Neuropsychiatry, Neurodegeneration

Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131647

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel